End-Stage Kidney Disease - Pipeline Insight, 2019 - ResearchAndMarkets.com

February 1, 2019

DUBLIN--(BUSINESS WIRE)--Feb 1, 2019--The “End-Stage Kidney Disease - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

End-Stage Kidney Disease - Pipeline Insight, 2019 offers a comprehensive insight of the pipeline (under development) therapeutics scenario and growth prospects across End-Stage Kidney Disease development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Scope of the Report

The report provides a snapshot of the pipeline development for the End-Stage Kidney Disease The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the End-Stage Kidney Disease The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for End-Stage Kidney Disease The report also covers the dormant and discontinued pipeline projects related to End-Stage Kidney Disease

Reasons to Buy

Establish comprehensive understanding of the pipeline activity across this End-Stage Kidney Disease to formulate effective R&D strategies Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of End-Stage Kidney Disease therapeutics Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Topics Covered

1. Report Introduction

2. End-Stage Kidney Disease Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for End-Stage Kidney Disease

4. Comparative Analysis

5. Products in Clinical Stage

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products

Product Description Research and Development Product Development Activities

Companies Mentioned

BLR Bio LLC CTI BioPharma Corp F. Hoffmann-La Roche Ltd Novartis AG Prolong Pharmaceuticals LLC VESSL Therapeutics Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fx6rm7/endstage_kidney?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190201005233/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Liver and Kidney Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS PHARMACEUTICAL

SOURCE: Research and Markets

PUB: 02/01/2019 07:14 AM/DISC: 02/01/2019 07:14 AM

http://www.businesswire.com/news/home/20190201005233/en